INTRODUCTION
β1,6-branching of asparagine-linked oligosaccharides is directly associated with metastasis [1, 2] . N-Acetylglucosaminyltransferase V (GnT-V ; EC 2.4.1.155) is a key enzyme in the processing of N-linked sugar chains during the synthesis of glycoproteins [3] . It catalyses the transfer of a GlcNAc residue from UDPGlcNAc to the α1,6-mannoside arm in acceptor N-glycans to form a β1,6-branched structure (Scheme 1).
The activity of GnT-V is increased in various malignant cells [4] and tissues [5, 6] , and the expression of GnT-V was found to be induced in the early stages of hepatocarcinogenesis [7] . Although the cloning of the cDNA of GnT-V and chromosomal mapping were achieved [8, 9] and there have been reports about its long-term regulation [10] , little is known about its short-term regulation.
Our previous work has shown that GnT-V is regulated by protein kinase C [11] . The activity of GnT-V in human hepatocarcinoma cells was increased after treatment of the cells with phorbol esters. The variation in GnT-V activity was in accordance with the activity of membranous protein kinase C, and could be blocked by protein kinase C inhibitors.
To further the study of the regulation of GnT-V, we have used two different stimulators of receptor tyrosine kinases, epidermal growth factor (EGF) and insulin [12, 13] , to treat 7919 rat hepatocellular carcinoma cells. Short-term regulation of GnT-V
Scheme 1 Action of GnT-V
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blocked the activation of mitogen-activated protein kinase by EGF, also blocked the activation of N-acetylglucosamyltransferase V by this hormone, whereas the activation of Nacetylglucosamyltransferase V by insulin could not be blocked by Et ") -OH $ . Our results suggest that N-acetylglucosamyltransferase V may be regulated by different receptor protein tyrosine kinase pathways.
by these hormones was detected. We also investigated whether these effects could be blocked by
, which blocks the activation of mitogen-activated protein kinase (MAP kinase) by EGF (X. Zhou, unpublished work).
EXPERIMENTAL Materials
RPMI-1640 medium was from Gibco. Bovine calf serum was from the Institute of Medical Radiology, Shanghai Medical University. The standard 2-aminopyridine (PA)-labelled oligosugar chains GlcNAcβ1-2Manα1-6(GlcNAcβ1-2Manα1-3)Man-β1-4GlcNAcβ1-4GlcNAc-PA and GlcNAcβ1-2(GlcNAcβ1-6)-Manα1-6(GlcNAcβ1-2Manα1-3) Manβ1-4GlcNAcβ1-4GlcNAc-PA (confirmed by NMR) were from Dr. N. Taniguchi (Department of Biochemistry, Medical School, Osaka University, Japan). Mannose, UDP-GlcNAc, GlcNAc, Mes, leupeptin and insulin were from Sigma. PMSF was from Merck. EGF was kindly donated by Dr. S. Higashiyama (Department of Biochemistry, Medical School, Osaka University, Japan). The HPLC apparatus LC-9A was a product of Shimazu.
Cell culture and preparation of crude enzyme
The 7919 rat hepatocellular carcinoma cell line was cultured as described previously [14, 15] . Quiescent cells were obtained by incubating 7919 cells for 48 h in 1640 medium supplemented with 0.5 % calf serum. The quiescent cells (preincubated or not with Et ") -OH $ ) were treated with EGF or insulin for the indicated periods. The cells were then washed with 0.9 % NaCl and homogenized with an ultrasonic disrupter in an adequate volume of buffer A (20 mM Tris\HCl, pH 7.4, containing 0.25 M sucrose, 2 mM EDTA, 10 mM EGTA, 2 mM dithiothreitol, 0.5 mM PMSF and 5 µg\ml leupeptin). Aliquots were taken for assay of GnT-V. Proteins were quantified by Lowry method [16] .
Figure 1 Product pattern of GnT-V activity
Samples of 100 µg of protein homogenate were added to a reaction cocktail, as described in the text. The reaction time was 5 h. S, substrate [GlcNAcβ1-2Manα1-6(GlcNAcβ1-2Manα1-
Assay of GnT-V
The substrate for GnT-V, the fluorescently labelled biantennary sugar chain GlcNAcβ1-2Manα1-6(GlcNAcβ1-2Manα1-3)Man-β1-4GlcNAcβ1-4GlcNAc-PA, was prepared as described [14, 17] . A previously described method for the assay of GnT-V activity was adopted [18] . The 50 µl reaction mixture contained 100 mM Mes (pH 6.25), 100 µM substrate, 50 mM UDP-GlcNAc, 0.2 M GlcNAc, 1 % Triton X-100 and 100 µg of crude enzyme protein prepared as described above. After incubation at 37 mC for 5 h, the reactions were stopped by heating at 100 mC for 3 min and the samples were centrifuged at 10 000 g in an Eppendorf tube for 15 min. An aliquot (20 µl of each sample) was applied to HPLC. Elution was performed at 55 mC with 10 mM ammonium acetate containing 0.125 % n-butanol for the first 10 min, followed by a gradient of n-butanol (0.125-0.500 %) in 10 mM ammonium acetate for 40 min and then with 0.500 % n-butanol in the same buffer for the final 10 min. The flow rate was 1 ml\min. The elution patterns of the reaction are shown in Figure 1 . The product was quantified as : (amount of the standard peak)i(area under product peak)\(area under standard peak). The specific activity of GnT-V was expressed as pmol of product\h per mg of protein.
RESULTS AND DISCUSSION

Time phase curve for the effect of EGF on GnT-V activity
Quiescent 7919 cells were treated with EGF (2.5 ng\ml) for 5, 10, 15, 20, 25 or 30 min, followed by assay of GnT-V activity. The activity of GnT-V increased gradually after treatment with EGF ( Figure 2 ). After 10 min of treatment, it had reached a maximum that was twice the activity before treatment, and activity remained high for 30 min.
The effect of EGF on GnT-V activity is blocked by Et 18 -OH 3
Quiescent 7919 cells were preincubated with Et ") -OH $ at a concentration of 10 µg\ml for 2 h. Then the cells were washed with 0.9 % NaCl three times, and treated with EGF. After 5 and 10 min, the cells were collected for assay of GnT-V activity (Table 1) . We found that, after 5 min of treatment with EGF, GnT-V activity in the cells not preincubated with Et ") -OH $ had increased, as shown in Figure 2 . However, in the cells preincubated with Et ") -OH $ , GnT-V activity could not be detected. After 10 min of treatment with EGF, GnT-V activity had increased greatly in the cells not preincubated with Et ") -OH $ , as shown in Figure 2 , but the activity in cells preincubated with Et ") -OH $ had only increased slightly and was lower than that in the control cells. Hormonal stimulation of N-acetylglucosaminyltransferase V activity
Time phase curve for the effect of insulin on GnT-V activity
Quiescent 7919 cells were treated with insulin (2 nM) for 5, 10, 15, 20, 25 or 30 min, followed by assay of GnT-V activity ( Figure  3 ). The activity of GnT-V increased after treatment, reaching a maximum at 5 min, and then fell gradually, but remained higher than before treatment.
The effect of insulin on GnT-V activity cannot be blocked by Et Quiescent 7919 cells were preincubated with Et ") -OH $ at a concentration of 10 µg\ml for 2 h. The cells were then washed with 0.9 % NaCl three times, and treated with insulin. After 5, 10, 15, 20, 25 and 30 min, the cells were collected for assay of GnT-V activity (Figure 3) . Preincubation with Et ") -OH $ had no effect on insulin-stimulated GnT-V activity.
EGF may cause the autophosphorylation of EGF receptors and their binding to SHC [19, 20] , which in turn binds to and phosphorylates phospholipase C-γ. Phospholipase C-γ catalyses the degradation of PtdIns(4,5)P # into diacylglycerol and Ins(1,4,5)P $ . Diacylglycerol activates protein kinase C, which may in turn activate GnT-V, as was shown in our previous work [11] . We propose that this is one of the pathways whereby EGF could activate GnT-V.
Another possible pathway for EGF is that its receptor binds to Grb protein. This protein may be bound to mSoS1 and mSoS2, in turn activating Ras and Raf proteins, and thus stimulate the MAP kinase pathway. Blocking the activation of Raf may abort the effect of EGF on GnT-V. This suggests that the regulation by EGF of GnT-V is related to the MAP kinase pathway.
The signal transduction pathways of insulin have not been fully elucidated, but they are definitely different from those of EGF. One pathway is that the insulin receptor binds to other signal molecules through insulin receptor substrate-1 [21] . Our research shows that insulin can regulate GnT-V activity but that its effect is not related to the blocking of activation of Raf.
In conclusion, we have shown that : (1) the activation of two different receptor kinases induces the activation of GnT-V ; (2) the time phases of activation by EGF and insulin are different ; and (3) Et ") -OH $ , a new anti-tumour ether lipid that prevents the binding of EGF-activated Raf protein to cell membranes, can Received 16 October 1996/8 January 1997 ; accepted 30 January 1997 block the effect of EGF, but not that of insulin, on GnT-V activity. This suggests that GnT-V may be regulated via different receptor protein kinase pathways. The detailed mechanisms involved remain to be studied.
